LEO 29102 + betamethasone dipropionate

LEO 29102 + betamethasone dipropionate is a topical combination therapy under investigation for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. LEO 29102 is a small molecule phosphodiesterase 4 (PDE4) inhibitor developed by Leo Pharma, designed to reduce inflammation by inhibiting PDE4 activity, which leads to decreased production of pro-inflammatory cytokines. Betamethasone dipropionate is a potent synthetic corticosteroid with strong glucocorticoid activity and minimal mineralocorticoid effects; it acts primarily through agonism of the glucocorticoid receptor, suppressing immune responses and inflammation in the skin[2][3][5]. The combination aims to leverage both anti-inflammatory mechanisms for enhanced efficacy in dermatological indications.